ivonescimab

all catalysts(0)

nothing on the calendar yet

News(10)

• Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
  Summit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated…
  endpoints · 10h ago
• Summit, Akeso’s China approval celebration cut short as survival benefit degrades
  Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines ove…
  biospace · 10h ago
• Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China
  Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
  raps · 5d ago
• Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
  After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…
  fiercebiotech · 19d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 21d ago
• Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
  Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…
  biospace · 24d ago
• Summit and Akeso sharpen case for ivonescimab with new Western data
  Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
  biospace · 26d ago
• STAT+: Pharma tries to tamp down broad China restrictions
  AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
  stat · 26d ago
• Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
  A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…
  biopharma_dive · 26d ago
• Summit reports two-year survival data for Western patients, though context lacking
  Summit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…
  endpoints · 26d ago